報價延遲最少15分鐘:2025/09/12 15:12 EDT
常規時段
|
|
|
|
|
||||||||||||
|
|
|
|
|
36.45 
|
|
|
| 價值評估 |
|
盈利(現時/預測)
-3.56/-2.85
|
|
企業價值
2.88B
|
| 資產負債 |
|
每股賬面淨值
4.04
|
| 現金流量 |
|
現金流量率
--
|
| 損益表 |
|
收益
0
|
|
每股收益
--
|
|
同行比較
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
報價延遲最少15分鐘：2025/09/12 15:12 EDT
同行比較之報價最少15分鐘延遲
|
業務概覽
|
|||
| Mineralys Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing medicines to target diseases driven by abnormally elevated aldosterone. The company's product candidate, lorundrostat, is a proprietary, orally administered, selective aldosterone synthase inhibitor, that is initially developed for the treatment of patients with uncontrolled hypertension, defined as individuals who are unable to achieve BP of below 130/80 mmHg despite taking two ormore lines of antihypertensive medication or resistant hypertension, typically including a diuretic. |
